TA-8995-206 (The VINCENT Study)

Recruiting
18 years - 75 years
All
Phase N/A
1 Location

Brief description of study

The primary objective is to evaluate the efficacy of obicetrapib alone for 8 weeks as compared to obicetrapib in combination with Evolocumab for an additional 8 weeks after initial obicetrapib treatment on percent change of Lp(a) levels from Baseline in people with mild dyslipidemia, defined as Lp(a) levels 50 mg/dL ( 125 nmol/L) and LDL-C levels 70 mg/dL ( 1.8 mmol/L) and 190 mg/dL ( 4.91 mmol/L).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 18 years - 75 years
  • Gender: All
Updated on 02 Apr 2026. Study ID: 24-1768

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center